Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jan 22;138(1):262–273.e6. doi: 10.1016/j.jaci.2015.11.018

FIG 7.

FIG 7

A and B, OVA-specific IgE (Fig 7, A) and IgG2a (Fig 7, B) production in mice epicutaneously (EC) treated with OVA and CpG after EC immunization with OVA alone. C and D, OVA-specific IgE (Fig 7, C) and IgG2a (Fig 7, D) secretion in recipients injected with regulatory ALNCs before immunization or before challenge with OVA. Fig 7, A and B, n = 6–8; Fig 7, C and D, n = 4–5. ns, Not significant. *P < .05, **P < .01, and ***P < .001.